Immune function enhancement testing provides the scientific evidence required to substantiate immunity-related health claims for health foods, dietary supplements, and functional ingredients. Using validated animal models, cellular assays, and human clinical trials, accredited third-party laboratories evaluate cellular, humoral, and nonspecific immune responses in accordance with national evaluation specifications and GB standards. This article explains the testing scope, sample types, methodologies, endpoint criteria, and practical applications of immune enhancement function assessment.
Technical Overview
Immune function enhancement testing is a standardized biological evaluation designed to determine whether a test substance can measurably strengthen immune function and thereby support an "enhances immune function" or "helps support immunity" health claim. In jurisdictions where functional claims on health foods and supplements are regulated, immunity enhancement is one of the most frequently declared functions, and regulatory approval depends on a defined battery of in vivo and in vitro assays performed under Good Laboratory Practice (GLP) principles.
The evaluation framework rests on four immunological pillars: cellular immunity (T-lymphocyte-mediated responses), humoral immunity (B-lymphocyte and antibody-mediated responses), nonspecific immunity (mononuclear-phagocyte system and granulocyte function), and natural killer (NK) cell activity. Healthy laboratory mice serve as the primary model, with the test article administered orally at multiple dose levels for a minimum of 30 days. A claim is substantiated when specified combinations of endpoints show statistically significant, biologically meaningful, and dose-consistent improvements without impairing body weight, immune organ indices, or other immune parameters.
Immune function studies are typically performed alongside a companion safety assessment conducted in accordance with the GB 15193 series of food safety toxicological standards, ensuring that any observed immune enhancement occurs without adverse effects. Studies are conducted by accredited third-party laboratories operating in compliance with ISO/IEC 17025 quality management requirements.
Testing Samples
Health Foods and Dietary Supplements
Finished dosage forms intended to carry an immunity claim, including tablets, hard and soft capsules, oral liquids, powders, granules, and gummies. Sample submissions typically require 30 to 60 finished units or 1 to 2 kilograms of bulk product, accompanied by compositional information, recommended human dosage, and physicochemical specifications.
Functional Ingredients and Raw Materials
Botanical and fungal extracts such as ginseng, astragalus, cordyceps, Ganoderma (lingzhi) and Echinacea; bioactive polysaccharides including yeast beta-glucan and fungal polysaccharides; animal-derived actives such as lactoferrin, bovine colostrum, and propolis; microalgal products such as spirulina and chlorella; and micronutrients with established immune roles, including vitamins C, D, and E, zinc, and selenium.
Probiotics and Fermented Products
Live microorganism preparations containing strains such as Lactobacillus and Bifidobacterium, postbiotic and heat-killed microbial preparations, and fermented dairy or plant-based products, where immune modulation is part of the intended functional profile.
Novel Foods and Special Formulas
Novel food ingredients undergoing regulatory approval, as well as special medical purpose formulas and nutritionally complete products where immune-related claims or physiological support statements require substantiation.
Testing Items
Core immune function endpoints are organized by immune mechanism and are selected as a package according to national health food evaluation specifications:
- Cellular immunity: concanavalin A (ConA)-induced spleen lymphocyte proliferation assay (MTT colorimetric method); delayed-type hypersensitivity (DTH) reaction induced by 2,4-dinitrofluorobenzene (DNFB); T-lymphocyte subset profiling (CD3, CD4, CD8) by flow cytometry
- Humoral immunity: serum hemolysin level (HC50) following sheep red blood cell immunization; plaque-forming cell (PFC) assay enumerating antibody-secreting spleen cells; quantitative determination of serum IgG, IgM, and IgA by ELISA or immunoturbidimetry
- Nonspecific immunity: carbon particle clearance test (clearance index and phagocytic index); peritoneal macrophage phagocytosis of chicken red blood cells (phagocytic rate and phagocytic index); neutrophil phagocytic function
- NK cell activity: lactate dehydrogenase (LDH) release assay using YAC-1 target cells at defined effector-to-target ratios
- Supporting observations: body weight and food intake throughout dosing; thymus and spleen organ-to-body-weight indices; hematology and serum chemistry; histopathological examination of immune organs where required
- Companion safety endpoints: acute oral toxicity, genotoxicity battery, and subchronic feeding studies per the GB 15193 series when required for registration dossiers
Testing Methods
Study Design and Dose Selection
Studies use specific pathogen-free (SPF) mice, commonly BALB/c, ICR, or KM strains, of both sexes, acclimatized for at least five days before dosing. Animals are randomized into a negative control group and three dose groups, typically set at 5-fold, 10-fold, and 30-fold the recommended human daily intake converted on a body-weight (mg/kg) basis, with the high dose remaining below levels producing toxicity or exceeding gavage volume limits. The test article is administered by oral gavage to match the intended human route of exposure for a minimum of 30 consecutive days, extended where the onset of immune modulation is expected to be slow. Where the evaluation design requires an immunosuppression model, an acquired immunodeficiency state is induced with cyclophosphamide or hydrocortisone to assess restorative capacity. Housing, feeding, and environmental conditions follow laboratory animal care standards, and all procedures are reviewed by the institutional animal ethics committee.
Cellular Immunity Assays
Spleen lymphocyte proliferation is measured by culturing isolated spleen cells with ConA and quantifying metabolic activity via MTT reduction; results are expressed as a stimulation index relative to unstimulated controls. Delayed-type hypersensitivity is evaluated by abdominal sensitization with DNFB followed by ear challenge, with the difference in ear thickness between challenged and untreated ears serving as the response metric. Flow cytometric immunophenotyping provides CD4/CD8 ratios as confirmatory cellular markers.
Humoral Immunity Assays
For the hemolysin assay, mice are immunized intraperitoneally with sheep red blood cells, and serum complement-mediated hemolysis is measured spectrophotometrically, with the half hemolytic dose (HC50) calculated as the antibody activity index. The plaque-forming cell assay counts antibody-secreting cells in the spleen using the Jerne method. Serum immunoglobulin classes are quantified to corroborate antibody-mediated responses.
Nonspecific Immunity Assays
The carbon clearance test evaluates mononuclear-phagocyte system activity by intravenous injection of diluted ink followed by serial blood sampling; the clearance index and corrected phagocytic index are derived from the rate of carbon disappearance from circulation. Peritoneal macrophage function is assessed by measuring the phagocytic rate and phagocytic index against chicken red blood cells in ex vivo preparations.
Natural Killer Cell Activity
Spleen effector cells are co-incubated with radiolabel-free YAC-1 target cells at defined effector-to-target ratios. NK-mediated cytolysis releases LDH into the culture supernatant, and the measured enzymatic activity is converted to a percentage cytotoxicity, providing a direct index of innate cytotoxic function.
Result Evaluation Criteria
A positive determination generally requires statistically significant improvement (p < 0.05 versus control) in the endpoint combinations prescribed by the applicable evaluation specification, such as at least one cellular immunity indicator combined with prescribed positive results across the remaining functional categories. A dose-response relationship strengthens the determination. Any significant deterioration in body weight, organ indices, or other immune endpoints disqualifies a positive conclusion, regardless of improvements elsewhere.
Human Clinical Trials
Where the regulatory pathway, claim type, or product nature requires human evidence, trials are conducted as randomized, double-blind, placebo-controlled studies in eligible adult volunteers with documented ethics approval and informed consent. Typical endpoints include lymphocyte subsets, serum immunoglobulins, complement components C3 and C4, NK cell activity, and the incidence and duration of common upper respiratory infections, assessed over intervention periods of 8 to 12 weeks or longer.
Applications
Immune function enhancement testing supports the full product lifecycle, from research and development to registration and market maintenance:
- Registration dossiers for health food approval supporting an immune enhancement function claim
- Claim substantiation for labeling, advertising compliance, and defense against regulatory or consumer challenges
- Research and development screening, including candidate ranking, formulation comparison, and dose optimization
- Technical documentation for ingredient suppliers promoting functional raw materials
- Evidence packages adapted to import and export market requirements across different regulatory regimes
- Supporting data for scientific publications, patents, and technology transfer agreements
- Post-market re-evaluation and quality consistency verification for established products
FAQ
How many samples are required for testing?
For finished products, laboratories typically request 30 to 60 retail units or 1 to 2 kilograms of bulk material, depending on the dosage form and the number of dose groups. Ingredient testing generally requires 2 to 5 kilograms of raw material. Samples should be accompanied by the certificate of analysis, formula, and recommended daily intake.
How long does the evaluation take?
A standard 30-day mouse study, including acclimatization, dosing, endpoint assays, and report preparation, typically requires 8 to 12 weeks. Human clinical trials require significantly longer timelines, generally several months including recruitment, intervention, and statistical analysis.
What constitutes a positive test result?
A positive result requires statistically significant and biologically meaningful improvement in the specified combination of immune endpoints, ideally with a dose-response trend, while all supporting indicators such as body weight and organ indices remain unimpaired. Evaluation specifications define which endpoint combinations are acceptable for claim substantiation.
Is safety testing required together with function testing?
For regulatory submissions, yes. Functional evaluation is normally accompanied by safety assessment under the GB 15193 series, which may include acute toxicity, genotoxicity, and subchronic feeding studies, depending on the product type and registration pathway.
Can testing be performed on ingredients rather than finished products?
Yes. Ingredients can be evaluated independently for research, monograph development, or supplier documentation purposes. However, when the objective is a claim on a finished product, the evaluation should use the finished product in its market-ready form to ensure the results are representative of consumer exposure.